Ashland enters its fiscal fourth-quarter report with a story that is half finished. Last quarter, sales, volumes and pricing all turned up at once, with every business unit growing. The profit side has not caught up. The fiscal 2026 report, due after the close on November 3, has to show that the revenue recovery is finally reaching the margin line, and that the troubled Hopewell plant is no longer eating the gains.
The Street is asking for a sharp earnings step-up on modest sales growth. Consensus calls for adjusted EPS of $1.30, up about 20% from $1.08 a year ago and well above the $1.02 earned last quarter, on revenue of roughly $500.7 million, up 4.7%. That sales forecast is conservative. Revenue barely moves from the prior quarter's $497 million, and growth would slow from the 7% pace Ashland just posted, even though the comparison is against a quarter when sales fell 8%. On revenue, the bar looks reachable. Management reaffirmed fiscal 2026 sales of $1.835 billion to $1.870 billion, and the $1.86 billion consensus sits in the upper half of that range. This suggests analysts believe the momentum holds without assuming any surprise.
Earnings are the harder ask. Adjusted EBITDA guidance of $385 million to $400 million has stayed put for three quarters, after an original range of $400 million to $430 million was cut. Last quarter, management also trimmed its adjusted EPS outlook to low-to-mid single-digit growth because of a higher tax rate and unfavorable discrete items. Group EBITDA margin slid to 21.9% from 24.4% a year earlier. Specialty Additives took the biggest hit, with its margin falling to 14.7% from 19.8% as the Hopewell HEC ramp ran below target and plant costs were spread over too little output. Management put about $40 million, or roughly 200 basis points of margin, at stake there. It said relief would begin no sooner than the second half of fiscal 2026 and mostly arrive in fiscal 2027. Any sign of better Hopewell productivity this quarter would support the recovery case. Another quarter of flat or shrinking Specialty Additives margins would push the payoff further out.
Pricing is the second checkpoint. It swung to a 1% gain last quarter after two quarters of declines, and management signaled stronger price capture in the fourth quarter. Positive pricing alongside steady volume would help explain how EPS can climb so far on low single-digit sales growth. Life Sciences, coming off 11% growth and a fifth straight quarter of higher pharma volume, has newer stories to watch. These include early traction for its sodium caprate permeation enhancer aimed at oral GLP-1 drugs and a revival in NMP demand tied to North American batteries and energy storage. Personal Care, where margin rose to 29%, needs to show that biofunctional actives can keep up their pace. Weak construction, energy and architectural coatings markets remain the soft spots.
Sentiment has warmed sharply, rising to 42.2% bullish from almost neutral before the last report. The stock has not followed. Shares are flat since the July results, trailing the S&P 500 by about 2.7 points, after a steep run from the high $40s in the prior quarter. At $72.99, the stock sits comfortably above its 200-day average near $63.46 and mid-range between $67 and $78.25, so it is not close to a breakout. Activist Ancora's two new board seats and a new capital allocation committee add a strategic angle that could attract attention on the call.
Because this report closes the fiscal year, any early comments on fiscal 2027 will matter as much as the quarter itself. The deciding question is simple. Can Ashland show that margins are starting to recover alongside sales, rather than asking investors to keep waiting for Hopewell to deliver?